Gut microbiome associations with clinical outcomes of CD19-targeted CAR-T cell immunotherapy

In order to discover and validate associations between the gut microbiome and the clinical outcomes of CD19-targeted CAR-T cell immunotherapy, we performed an international, multi-center cross-sectional clinical study. Stool samples of patients were collected before and over the course of CAR-T cell therapy, and the associations of the gut microbiome with therapy responses and the occurrence of immune-related side effects were analyzed.